Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jaguar Health (JAGX) Amortization of Deferred Charges (2017 - 2024)

Historic Amortization of Deferred Charges for Jaguar Health (JAGX) over the last 9 years, with Q1 2024 value amounting to $274000.0.

  • Jaguar Health's Amortization of Deferred Charges fell 7852.66% to $274000.0 in Q1 2024 from the same period last year, while for Dec 2024 it was $274000.0, marking a year-over-year decrease of 9792.52%. This contributed to the annual value of $274000.0 for FY2024, which is 9792.52% down from last year.
  • Latest data reveals that Jaguar Health reported Amortization of Deferred Charges of $274000.0 as of Q1 2024, which was down 7852.66% from $1.7 million recorded in Q4 2023.
  • Over the past 5 years, Jaguar Health's Amortization of Deferred Charges peaked at $7.1 million during Q3 2023, and registered a low of $174000.0 during Q2 2020.
  • Moreover, its 5-year median value for Amortization of Deferred Charges was $1.5 million (2021), whereas its average is $1.9 million.
  • The largest annual percentage gain for Jaguar Health's Amortization of Deferred Charges in the last 5 years was 148160.0% (2020), contrasted with its biggest fall of 9529.86% (2020).
  • Quarter analysis of 5 years shows Jaguar Health's Amortization of Deferred Charges stood at $2.0 million in 2020, then decreased by 22.21% to $1.5 million in 2021, then surged by 92.91% to $3.0 million in 2022, then crashed by 42.37% to $1.7 million in 2023, then crashed by 83.98% to $274000.0 in 2024.
  • Its Amortization of Deferred Charges stands at $274000.0 for Q1 2024, versus $1.7 million for Q4 2023 and $7.1 million for Q3 2023.